American Society of Hirudotherapy

Mid-Substance Achilles Tendinopathy

Investigational use for chronic mid-substance Achilles tendinopathy; evidence limited to isolated single-patient reports.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 17, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for Achilles tendinopathy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational; only isolated single-patient reports exist.
What evidence exists?
No peer-reviewed clinical study of leech therapy in Achilles tendinopathy was identified; the few human reports found are isolated single-patient case studies. Tier C (investigational). There are no controlled trials. Evidence-based first-line management is an eccentric calf-loading program (Alfredson protocol or heavy-slow resistance), with extracorporeal shockwave therapy for non-responders. Insertional tendinopathy responds less well to eccentric loading; PRP and surgical options have varying evidence.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the posterior calf and Achilles area for 5 to 14 days
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Temporary worsening of Achilles pain after the procedure
  • Substitution for eccentric loading or shockwave therapy, which have stronger evidence
  • Risk if a leech is placed too close to a small tendon rupture or partial tear
  • Delay of orthopedic evaluation if rupture is suspected
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Tendon rupture if leeches are placed inappropriately or if tendon is already significantly degenerated
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
Who should not consider this
  • Patients with suspected or confirmed acute Achilles rupture (surgical or orthopedic evaluation)
  • Patients within 4 weeks of local corticosteroid injection
  • Patients with insertional Achilles tendinopathy (response is poorer; consider shockwave or surgical evaluation)
  • Patients with active Achilles bursitis or infection
  • Patients on anticoagulants or with anemia
  • Patients who have not engaged with an eccentric loading program
  • Patients with imaging-confirmed partial tendon tear (different management needed)
What to ask your clinician
  • Have I had a confirmed diagnosis of mid-substance tendinopathy by exam and ultrasound or MRI?
  • Have I completed at least 12 weeks of structured eccentric calf loading?
  • Has extracorporeal shockwave therapy been considered?
  • Has PRP or surgical evaluation been considered for refractory cases?
  • Where exactly will the leech be placed — confirm mid-substance, not insertional?
  • What is the realistic expected VISA-A score change, given that only single-patient reports exist?
  • Has ultrasound or MRI excluded a partial tendon tear?
  • What is the rupture risk in a degenerated tendon, and how is it minimized?
When to seek urgent care
  • Sudden snap or pop in the calf with inability to push off the foot (rule out Achilles rupture)
  • Severe sudden calf pain with swelling (rule out Achilles rupture or DVT)
  • Loss of plantar flexion strength on testing
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, warmth, pus, or red streaks at any bite site
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)

What this does NOT mean

  • It does not replace an eccentric calf-loading program, which is the evidence-based foundation.
  • It does not heal a complete or partial Achilles tendon rupture; that needs orthopedic management.
  • It is less effective for insertional Achilles tendinopathy.
  • Only isolated single-patient reports exist; benefit beyond placebo or concurrent therapy is unknown.

Clinical Profile

Category
Musculoskeletal
ICD-10
M76.61, M76.62
Safety tier
Low

Evidence Summary

No controlled clinical trial or case series of leech therapy for chronic Achilles tendinopathy was identified in PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov or Russian- and German-language web searches; the only Achilles-specific case report found in journal literature is a single-patient Ayurvedic case study from 2025 (Achilles tendinitis, relief reported without scores), so there is no reliable evidence of improvement in VISA-A scores or pain. Any proposed mechanism (anti-inflammatory salivary peptides, reduction of peri-tendinous edema, or modulation of neovessel-driven nociception) is speculative and unproven in this condition. Evidence-based management — progressive eccentric/heavy-slow loading, activity modification, and extracorporeal shockwave therapy for recalcitrant cases — remains first-line. ASH position: any use of leech therapy for Achilles tendinopathy is investigational and supported only by isolated single-patient reports.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Acute Achilles tendon rupture (surgical)
  • Recent local corticosteroid injection (<4 weeks)
  • Acute or partial Achilles tear (MRI confirmation needed; surgical or boot management)
  • Fluoroquinolone-associated tendinopathy (taper drug; avoid invasive intervention until resolved)

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.